US2021093655A1PendingUtilityA1
Particles with RNA Cleaving Nucleobase Polymers and Uses for Managing Inflammatory Disorders
Est. expiryMay 24, 2036(~9.8 yrs left)· nominal 20-yr term from priority
A61K 9/0078A61K 9/51B82Y 5/00C07H 21/04A61K 9/008A61P 11/06A61K 31/712A61K 9/141A61K 45/06A61K 9/007A61K 31/713A61K 9/0073A61K 9/0075
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
This disclosure relates to nucleobase polymers useful for degrading GATA-3 mRNA. In certain embodiments, this disclosure relates to nucleobase polymers and nanoparticles conjugated to nucleobase polymers disclosed herein. In certain embodiments, the nucleobase polymers or nanoparticles can be used in methods of managing disorders associated with excessive GATA-3 expression in inflammatory disorders and respiratory disorders such as asthma.
Claims
exact text as granted — not AI-modifiedWhat we claim is:
1 . A method of treating asthma comprising administering an effective amount of a nanoparticle coated with a nucleobase polymer comprising a sequence selected from SEQ ID NO: 1-49 to a subject in need thereof.
2 . The method of claim 1 wherein the nucleobase polymer has SEQ ID NO: 10 (GGCTTATTCAGGCTAGCTACAACGAAGATGGGG).
3 . The method of claim 1 wherein the nucleobase polymer has SEQ ID NO: 20 (ATTCCTTAAAGGCTAGCTACAACGATTCTTGGC).
4 . The method of claim 1 wherein the nucleobase polymer has SEQ ID NO: 30 (TCTTTTCTTAGGCTAGCTACAACGATTTGGTGC).
5 . The method of claim 1 , wherein administration is in combination with a second respiratory agent.
6 . The method of claim 5 , wherein the second respiratory agent is a corticosteroid, bronchodilator, albuterol, ipratropium, or combinations thereof.
7 . The method of claim 1 , wherein the subject is a human subject.Join the waitlist — get patent alerts
Track US2021093655A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.